Casdin Capital TEM Position
Active3-Fund ConvergenceCasdin Capital held their position in Tempus AI, Inc. (TEM) in Q4 2025, holding $17.4M worth of shares across 294,127 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
TEM is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for A2B530 in 259 days (Dec 31, 2026), making the timing of Casdin's position particularly relevant.
Short interest stands at 18.8% of float with 4.5 days to cover, indicating significant bearish positioning against Casdin's long thesis.
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Full company profile →Short Interest
18.8%
4.5 days to cover
Casdin Capital TEM Position History
Frequently Asked Questions
Does Casdin Capital own TEM?
Yes. As of Q4 2025, Casdin Capital holds 294,127 shares of Tempus AI, Inc. (TEM) valued at $17.4M. This data comes from their SEC 13F filing.
How many hedge funds own TEM?
3 specialist biotech hedge funds currently hold TEM, including RTW Investments, Perceptive Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy TEM?
Casdin Capital's position in TEM was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's TEM position increasing or decreasing?
Casdin Capital held their TEM position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TEMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →